Search

Your search keyword '"de Gruijl, Tanja D."' showing total 623 results

Search Constraints

Start Over You searched for: Author "de Gruijl, Tanja D." Remove constraint Author: "de Gruijl, Tanja D." Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
623 results on '"de Gruijl, Tanja D."'

Search Results

101. Correction: Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody

102. Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features

103. In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma.

104. Human Bone Marrow-Derived Myeloid Dendritic Cells Show an Immature Transcriptional and Functional Profile Compared to Their Peripheral Blood Counterparts and Separate from Slan+ Non-Classical Monocytes

105. Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer

107. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells

109. Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I–II Melanoma: Data from Two Randomized Phase II Trials

112. Highly specific and potently activating V gamma 9V delta 2-T cell specific nanobodies for diagnostic and therapeutic applications

114. Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression

121. High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status

122. Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival

124. TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients

126. Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells

128. Chronic Lymphocytic Leukemia (CLL) Cells Are Susceptible to γδ-T Cell Mediated Killing, Provided CLL-Derived γδ-T Cell Dysfunction Can be Reversed

130. Adjuvant treatment of early-stage melanoma by local i.d. administration of low-dose CpG-B and GM-CSF increases recurrence-free survival: long-term follow-up of three randomized clinical trials

131. Counteracting breast-cancer induced immune suppression by reactivating lymph node-resident conventional dendritic cells (LNR-cDC)

132. Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR

133. Langerin-mediated internalization of a modified peptide routes antigens to early endosomes and enhances cross-presentation by human Langerhans cells

141. Profiling of suppressive immune subsets in metastasis negative and positive sentinel lymph nodes from patients with HER2- breast cancer

144. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

147. MUTZ-3 Langerhans Cell Maturation and CXCL12 Independent Migration in Reconstructed Human Gingiva.

150. Clinical and Immunological Results Of a Phase I/IIa Study Of Allogeneic Dendritic Cell (DC) Vaccination, An “off The shelf” Treatment To Prevent Or Delay Relapse In Elderly Patients With Acute Myeloid Leukemia

Catalog

Books, media, physical & digital resources